Supernus to acquire NV-5138 assets from Navitor, with up to $350 million in milestone payments
On April 1, 2026, Supernus Pharmaceuticals entered into an asset purchase agreement with Navitor Pharmaceuticals to acquire rights to the compound NV-5138 or SPN-820, including intellectual property, inventory, regulatory materials and certain contract rights. The filing says the price consists of Supernus completing one Phase 2b study and making milestone payments of up to $350 million, and that Supernus can stop pursuing the compound if it judges the study unsuccessful. The filing reports no revenue or earnings figures, so the effect on shareholders depends on the study results and milestone achievement.
Key points
- Agreement dated April 1, 2026, with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC
- Purchase price: completion of one Phase 2b study plus milestone payments of up to $350 million
- Supernus has no further obligation to pursue milestones or commercialization if it judges the post-study result unsuccessful
- Agreement is filed as Exhibit 2.1, with some schedules and portions omitted
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.